- 세레브로리진 주
- Cerebrolysin® inj.
- Classification
- Central Nervous Agents
Indication/Usage
senile dementia of Alzheimer's type, Post-apoplectic complications, Craniocerebral trauma(post-operative trauma, cerebral contusion or concussion)
Dosage/Administration
Daily recommendations/Daily dose:
Senile dementia of Alzheimer's type, Post-apoplectic complications : 5~20mL
Craniocerebral trauma(post-operative trauma, cerebral contusion or concussion) : 10~50mL
Children : 1~2mL
The effectiveness of therapy can be increased by repeated courses, until no further benefit results. After the initial course, the frequency of doses may be reduced to 2 or 3 times per week. A treatment-free period, equal in length to the therapy course, should be allowed between successive therapy courses.
Doses of up to 5 ml IM and up to 10 ml undiluted IV may be given. Doses between 10 ml up to a maximum of 30 ml are recommended only as a slow intravenous infusion given a period of 60minutes, after dilution with 0.9 NaCl, Ringer's solution, 5% Glucose(or dextran).
Vitamins and cardiovascular drugs may be given concomitantly with Cerebrolysin but the drugs should not be mixed with Cerebrolysin in the syringe.
- Development Marketing Dept(Product information)
- +82-2-566-7199